PROJECT SUMMARY – OVERALL Rated Exceptional at both the 2013 (impact score, 19) and 2018 (impact score, 14) renewals of the Cancer Center Support Grant (CCSG), and receiving a two-year MERIT extension from the National Cancer Institute (NCI) in 2022, the Wistar Cancer Center continues an exponential path of research excellence. Leveraging a deep-rooted culture of collaboration, a nearly complete equivalence between The Wistar Institute and the Cancer Center, and a unified leadership structure where an experienced Cancer Center Director is also Institute President and Chief Executive Officer, the Cancer Center functions as a catalyst for innovation in basic and translational cancer research with broad societal impact. An unprecedented institutional commitment of over $81 million during the last five years enabled the recruitment of 17 new Cancer Center members at all academic ranks, transformed the technological and scientific capabilities of all 8 CCSG-supported Shared Resources, and strategically realigned Cancer Center Programs for maximal transdisciplinary collaboration with the launch of a new Genome Regulation and Cell Signaling (GRCS) Program. The Wistar Cancer Center of 2025 comprises 32 members and has a total funding base of $14,610,429. Peer-reviewed, cancer-related funding stands at $12,120,630 (83%), of which $6,765,960 is from the NCI translating into a strong cancer focus of 55%. As collaboration is a foundational hallmark of the Cancer Center, 77% of peer-reviewed, cancer-related funding and 37% of discovery publications are the product of collaboration. Currently, Wistar is the only NCI-designated “basic” Cancer Center to contribute to two Specialized Programs of Research Excellence (SPORE), three NCI program project grants, two NCI consortium grants and twenty-nine multi-investigator R01 awards (22 from the NCI, 76%). Building on these advances, the Cancer Center achieved unique societal impact during the last CCSG budget period. Groundbreaking disc